Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

MELBOURNE, Australia and OXFORD, United Kingdom, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing precisely targeted next-generation immunotherapies for the treatment of food allergy, today announces the appointment of Aled Williams as Chief Business Officer as the company continues its development into an international leader in food allergies. Aled’s appointment follows the establishment of the Company’s UK subsidiary at the Oxford Science Park and marks another ...